NEW: Premarket Now Starts at 4AM!

We’re excited to announce the extension of premarket and aftermarket hours! Our members now have access to quotes daily from 4:00 AM to 8:00 PM ET — offering greater flexibility and deeper insights into market trends beyond regular trading hours.

Upgrade to FINVIZ*Elite to access premarket quotes »

CLLS

Cellectis ADR

Apr 23 • 04:00PM ET

1.46

Dollar change +0.02
Percentage change 1.39	%

Healthcare • Biotechnology • France • NASD

Peers: CRSP NTLA SGMO BLUE EDIT QURE RCKT CYTK ADAP ARCT

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-0.40	Insider Own	10.28%	Shs Outstand	100.09M	Perf Week	0.00%
Market Cap	105.25M	Forward P/E	-	EPS next Y	-1.08	Insider Trans	0.00%	Shs Float	64.68M	Perf Month	11.45%
Income	-36.76M	PEG	-	EPS next Q	-0.15	Inst Own	17.74%	Short Float	0.70%	Perf Quarter	-4.58%
Sales	41.51M	P/S	2.54	EPS this Y	-8.54%	Inst Trans	24.49%	Short Ratio	1.29	Perf Half Y	-23.16%
Book/sh	1.31	P/B	1.12	EPS next Y	-142.25%	ROA	-10.12%	Short Interest	0.46M	Perf Year	-42.75%
Cash/sh	3.61	P/C	0.40	EPS next 5Y	-	ROE	-34.08%	52W Range	1.10 - 3.38	Perf YTD	-18.89%
Dividend Est.	-	P/FCF	5.38	EPS past 5Y	29.94%	ROI	-17.01%	52W High	-56.80%	Beta	2.96
Dividend TTM	-	Quick Ratio	1.73	Sales past 5Y	1118.47%	Gross Margin	52.18%	52W Low	32.73%	ATR (14)	0.09
Dividend Ex-Date	-	Current Ratio	1.73	EPS Y/Y TTM	77.93%	Oper. Margin	-175.32%	RSI (14)	59.34	Volatility	4.97% 6.47%
Employees	222	Debt/Eq	0.84	Sales Y/Y TTM	5397.35%	Profit Margin	-88.57%	Recom	2.00	Target Price	5.70
Option/Short	Yes / Yes	LT Debt/Eq	0.65	EPS Q/Q	109.91%	Payout	-	Rel Volume	0.17	Prev Close	1.44
Sales Surprise	236.94%	EPS Surprise	8.06%	Sales Q/Q	4393.29%	Earnings	Mar 13 AMC	Avg Volume	352.18K	Price	1.46
SMA20	10.45%	SMA50	8.63%	SMA200	-19.04%	Trades		Volume	59,440	Change	1.39%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-17-23	Initiated	Bryan Garnier	Buy	$6
May-18-22	Upgrade	Robert W. Baird	Neutral → Outperform	$10
Jan-06-22	Downgrade	Wells Fargo	Overweight → Equal Weight	$39 → $16
Nov-30-21	Initiated	JMP Securities	Mkt Outperform	$20
Nov-08-21	Downgrade	William Blair	Outperform → Mkt Perform
Oct-08-21	Downgrade	Robert W. Baird	Outperform → Neutral	$39 → $10
Apr-28-21	Downgrade	Guggenheim	Buy → Neutral
Mar-16-21	Upgrade	Robert W. Baird	Neutral → Outperform	$23 → $39
Aug-19-20	Upgrade	Citigroup	Neutral → Buy	$15 → $32
May-12-20	Initiated	Robert W. Baird	Outperform	$20
Mar-06-20	Downgrade	Goldman	Neutral → Sell	$15 → $11
Oct-30-19	Resumed	Guggenheim	Buy	$28
Aug-09-19	Initiated	BTIG Research	Buy	$37
May-24-19	Resumed	Citigroup	Neutral	$22
Mar-14-19	Initiated	William Blair	Outperform
Dec-19-18	Initiated	Goldman	Neutral
Jul-16-18	Initiated	Barclays	Overweight	$50
Mar-16-18	Initiated	Guggenheim	Neutral
Sep-05-17	Reiterated	Wells Fargo	Outperform	$33 → $40
Sep-05-17	Downgrade	SunTrust	Buy → Hold

Show Previous Ratings

Apr-22-25 09:00AM	Cellectis Charts Course for 2025 With Boost From AstraZeneca Deal (MarketBeat)
Apr-21-25 05:02PM	Cellectis SA (CLLS) Q4 2024 Earnings Call Highlights: Strategic Collaborations and Financial ... (GuruFocus.com)
Apr-07-25 04:30PM	Monthly information on share capital and company voting rights (GlobeNewswire) +5.00%
Mar-13-25 06:07PM	Cellectis Reports Financial Results for the Fourth Quarter and Full Year 2024 and Provides a Business Update (GlobeNewswire)
Mar-07-25 04:30PM	Cellectis to Report Fourth Quarter and Full Year 2024 Financial Results on March 13, 2025 (GlobeNewswire)
04:30PM	Loading…
Mar-06-25 04:30PM	Monthly information on share capital and company voting rights (GlobeNewswire)
Feb-24-25 01:30AM	Cellectis Presents 'Smart CAR T' Strategy to Enhance Efficacy Against Solid Tumors at AACR-IO 2025 (GlobeNewswire)
Feb-04-25 04:30PM	Monthly information on share capital and company voting rights (GlobeNewswire)
Jan-28-25 08:00AM	Totus Medicines Appoints Simon Harnest, MSc, BSc, as Chief Financial Officer (GlobeNewswire)
Jan-08-25 04:30PM	Monthly information on share capital and company voting rights (GlobeNewswire) -8.10%
Jan-07-25 11:28AM	Do Options Traders Know Something About Cellectis (CLLS) Stock We Don't? (Zacks)
Dec-29-24 08:24AM	Analysts Predict 400% Upside Potential for This Penny Stock (GuruFocus.com)
Dec-10-24 04:30PM	Cellectis announces the drawdown of the third tranche of 5 million under the credit facility agreement entered with the European Investment Bank (EIB) (GlobeNewswire)
Dec-04-24 04:30PM	Monthly information on share capital and company voting rights (GlobeNewswire)
Nov-06-24 04:38PM	Monthly information on share capital and company voting rights (GlobeNewswire)
04:30PM	Loading…
Nov-05-24 04:30PM	Cellectis Presents Multiple Strategies to Enhance CAR T-cell Efficacy in Solid Tumors at the SITC Annual Meeting (GlobeNewswire)
Nov-04-24 04:30PM	Cellectis Provides Business Updates and Financial Results for Third Quarter 2024 (GlobeNewswire)
07:14AM	What To Expect From Cellectis SA (CLLS) Q3 2024 Earnings (GuruFocus.com)
Oct-30-24 04:30PM	Cellectis to Report Third Quarter 2024 Financial Results on November 4, 2024 (GlobeNewswire)
Oct-23-24 06:29AM	Cellectis Presents New Gene-Editing Breakthroughs (TipRanks) +9.44%
Oct-22-24 02:00AM	Cellectis to Present Data on TALE-Base Editors and Non-Viral Gene Therapy at the ESGCT 31st Annual Congress (GlobeNewswire)
Oct-02-24 04:30PM	Monthly information on share capital and company voting rights (GlobeNewswire)
Sep-04-24 04:30PM	Monthly information on share capital and company voting rights (GlobeNewswire)
Sep-03-24 04:30PM	Cellectis Presents Pre-Clinical Evidence of MUC1 CAR T-cells Reducing Triple-Negative Breast Cancer While Preserving Safety (GlobeNewswire) -5.83%
Aug-26-24 04:30PM	Cellectis Publishes a Molecular Therapy Article on a SMART DUAL CAR T-cell Approach for Treating Recalcitrant Solid Tumors (GlobeNewswire)
Aug-07-24 02:00AM	Cellectis Appoints Dr. Adrian Kilcoyne as Chief Medical Officer (GlobeNewswire)
Aug-06-24 04:30PM	Cellectis Provides Financial Results for the Second Quarter 2024 (GlobeNewswire)
Aug-05-24 04:30PM	Monthly information on share capital and company voting rights (GlobeNewswire)
Aug-02-24 09:53AM	Cellectis starts alemtuzumab revival with FDA orphan drug win in leukaemia (Pharmaceutical Technology)
Aug-01-24 04:30PM	FDA Grants Orphan Drug Designation to Cellectis' CLLS52 (alemtuzumab) For ALL Treatment (GlobeNewswire)
04:30PM	Loading…
Jul-25-24 04:30PM	FDA Grants Orphan Drug and Rare Pediatric Disease Designation Status to Cellectis' UCART22 product candidate for Acute Lymphoblastic Leukemia (ALL) Treatment (GlobeNewswire) +12.20%
Jul-10-24 09:35AM	Down -22.78% in 4 Weeks, Here's Why You Should You Buy the Dip in Cellectis (CLLS) (Zacks)
Jul-05-24 04:30PM	Monthly information on share capital and company voting rights (GlobeNewswire)
Jun-28-24 04:30PM	Cellectis Reports Results from Shareholders Meeting Held on June 28, 2024 (GlobeNewswire)
Jun-20-24 04:30PM	Cellectis Publishes a Scientific Article Unveiling Three Key Factors for Efficient TALE Base Editing (GlobeNewswire)
Jun-18-24 12:00PM	Cellectis (CLLS) Upgraded to Buy: Here's Why (Zacks) -5.84%
09:35AM	After Plunging -27.95% in 4 Weeks, Here's Why the Trend Might Reverse for Cellectis (CLLS) (Zacks)
Jun-12-24 04:30PM	Cellectis Unveils a Non-Viral Gene Therapy Approach for Sickle Cell Disease in Nature Communications (GlobeNewswire)
Jun-05-24 04:30PM	Monthly information on share capital and company voting rights (GlobeNewswire) +6.23%
Jun-04-24 04:30PM	Cellectis Receives Orphan Drug Designation for UCART22, its Allogeneic CAR T Product for Patients with Acute Lymphoblastic Leukemia (GlobeNewswire)
May-29-24 04:30PM	Cellectis' Annual Shareholders General Meeting to be Held on June 28, 2024 (GlobeNewswire)
May-28-24 08:52PM	CLLS Stock Earnings: Cellectis Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace)
04:30PM	Cellectis Reports Financial Results for First Quarter 2024 (GlobeNewswire)
May-27-24 04:30PM	Cellectis to Report First Quarter 2024 Financial Results on May 28, 2024 (GlobeNewswire)
May-16-24 04:30PM	Monthly information on share capital and company voting rights (GlobeNewswire)
May-06-24 04:30PM	Monthly information on share capital and company voting rights (GlobeNewswire) +12.04% -7.46%
04:22AM	Cellectis Secures $140 Million Additional Equity Investment From AstraZeneca (MT Newswires)
02:00AM	Cellectis Announces Completion of the Additional Equity Investment by AstraZeneca (GlobeNewswire)
May-03-24 06:10AM	Cellectis CFO Bing Wang Retires, Interim CFO Appointed (MT Newswires)
May-02-24 04:30PM	Cellectis Appoints Arthur Stril as Interim Chief Financial Officer (GlobeNewswire) +17.90%
Apr-29-24 10:53PM	CLLS Stock Earnings: Cellectis Misses EPS, Misses Revenue for Q4 2023 (InvestorPlace)
04:46PM	Cellectis Reports Financial Results for the Fourth Quarter and Full Year 2023 (GlobeNewswire)
Apr-22-24 04:30PM	Cellectis Presents Novel TALEN Editing Processes Enabling Highly Efficient Gene Correction and Gene Insertion in HSPCs (GlobeNewswire)
Apr-10-24 04:30PM	Cellectis Publishes a Novel Intronic Gene Editing Approach For the Treatment of Inborn Metabolic Diseases by Edited HSPCs (GlobeNewswire)
Apr-08-24 04:30PM	Cellectis Announces Two Poster Presentations on Novel TALEN Editing Process for Gene Correction and Gene Insertion in HSPCs at the ASGCT Annual Meeting (GlobeNewswire)
Apr-04-24 04:30PM	Monthly information on share capital and company voting rights (GlobeNewswire)
Mar-04-24 04:30PM	Monthly information on share capital and company voting rights (GlobeNewswire)
Feb-02-24 04:30PM	Monthly information on share capital and company voting rights (GlobeNewswire)
Jan-16-24 04:30PM	Cellectis announces the drawdown of the second tranche of 15 million under the credit facility agreement entered with the European Investment Bank (EIB) (GlobeNewswire) -5.42%
Jan-08-24 04:30PM	Monthly information on share capital and company voting rights (GlobeNewswire)
Dec-22-23 04:30PM	Cellectis Reports Results from Shareholders Meeting Held on December 22, 2023 (GlobeNewswire)
Dec-01-23 04:30PM	Monthly information on share capital and company voting rights (GlobeNewswire) -5.59%
Nov-17-23 04:30PM	Cellectis' Shareholders Meeting to be Held on December 22, 2023 (GlobeNewswire) +11.83% +5.80%
Nov-15-23 02:30AM	Cellectis Announces the execution of the Subsequent Investment Agreement with AstraZeneca (GlobeNewswire) +9.38%
Nov-06-23 04:30PM	Cellectis Reports Financial Results for Third Quarter and First Nine Months 2023 (GlobeNewswire) -13.41%
Nov-03-23 04:30PM	Monthly information on share capital and company voting rights (GlobeNewswire)
Nov-02-23 04:30PM	Cellectis to Present Preliminary Results of NATHALI_01 and Updated Results of the BALLI_01 Phases I Trials at the American Society of Hematology (ASH) 65th Annual Meeting (GlobeNewswire) +14.02%
Nov-01-23 04:30PM	Cellectis to Report Third Quarter 2023 Financial Results on November 6, 2023 (GlobeNewswire) +172.16%
08:13AM	Why Is Cellectis (CLLS) Stock Up 175% Today? (InvestorPlace)
08:02AM	AstraZeneca takes 22% stake in Cellectis as part of collab for 10 cell and gene therapies (FierceBiotech.com)
03:00AM	Cellectis Announces Strategic Collaboration and Investment Agreements with AstraZeneca (GlobeNewswire)
Oct-31-23 04:30PM	Cellectis Presents Pre-Clinical Data on Multi-armored Allogeneic MUC1-CAR T-cells Targeting Triple-Negative Breast Cancer at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting (GlobeNewswire)
Oct-24-23 04:30PM	Cellectis to Present Pre-Clinical Data on HSPC Gene Therapy Program and Comprehensive Analysis of TALE-BE at the ESGCT 30th Annual Congress (GlobeNewswire) -12.50%
Oct-12-23 04:30PM	Cellectis and Imagine Institute Publish A Proof-Of-Concept Study of a Gene Surgery Candidate to Treat Activated Phosphoinositide 3-Kinase Syndrome Type 1 (APDS1) (GlobeNewswire)
Oct-03-23 04:30PM	Monthly information on share capital and company voting rights (GlobeNewswire) -7.79%
09:55AM	These 2 Strong Buy Penny Stocks Could Gain Over 500%, Says Baird (TipRanks)
Sep-27-23 04:30PM	Cellectis to Present Pre-Clinical Data on Multi-armored Allogeneic MUC1-CAR T-cells Targeting Triple-Negative Breast Cancer at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting (GlobeNewswire)
Sep-05-23 04:30PM	Monthly information on share capital and company voting rights (GlobeNewswire) -8.96%
Aug-07-23 04:30PM	Cellectis Provides Full Report for Second Quarter 2023 Financial Results (GlobeNewswire)
Aug-03-23 04:30PM	Cellectis Provides Business Updates and Preliminary Financial Results for Second Quarter 2023 (GlobeNewswire) -5.13%
Aug-01-23 04:30PM	Monthly information on share capital and company voting rights (GlobeNewswire) -6.07%
Jul-27-23 04:30PM	Cellectis to Report Second Quarter 2023 Financial Results on August 3, 2023 (GlobeNewswire)
Jul-12-23 04:30PM	Cellectis Appoints Dr. Cécile Chartier, Ph.D. to its Board of Directors (GlobeNewswire) +6.02%
Jun-28-23 04:30PM	Cellectis S.A. Reports Results from Annual Shareholders General Meeting Held on June 27, 2023 (GlobeNewswire)
Jun-13-23 04:30PM	Monthly information on share capital and company voting rights (GlobeNewswire)
Jun-09-23 04:30PM	Cellectis Presents Updated Clinical and Translational Data on BALLI-01 at the European Hematology Association (EHA) 2023 (GlobeNewswire)
Jun-05-23 04:30PM	Cellectis Showcased Preclinical Data at an Oral Presentation and Two Poster Presentations at the 29th International Society for Cell & Gene Therapy (ISCT 2023) Annual Event (GlobeNewswire)
May-31-23 04:50PM	Cellectis Publishes an Article in Cancer Immunology Research Demonstrating Preclinical Evidence of UCART20x22 Product Candidate to Target a Broad Spectrum of Patients with B-cell Malignancies (GlobeNewswire)
May-17-23 04:30PM	Cellectis Presents Clinical Data on AMELI-01 and Preclinical Data on Multiplex Engineering for Superior Generation of CAR T-cells at ASGCT 2023 (GlobeNewswire)
May-12-23 01:30AM	Cellectis Publishes Article in Frontiers in Immunology Unveiling Pre-Clinical Data on a Novel Treatment Paradigm for Successful CAR T Immunotherapy Against Stroma-rich Solid Tumors (GlobeNewswire)
May-11-23 10:20AM	Cellectis Announces Poster Presentation on BALLI-01 at the European Hematology Association (EHA) 2023 (GlobeNewswire) -5.73%
May-10-23 04:30PM	Monthly information on share capital and company voting rights (GlobeNewswire)
May-04-23 04:30PM	Cellectis Provides Business Update and Reports Financial Results for First Quarter 2023 (GlobeNewswire)
May-02-23 04:35PM	Cellectis Announces Oral Presentation on AMELI-01 and Poster Presentation on Multiplex Engineering for Superior Generation of CAR T-cells at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting (GlobeNewswire) -6.41%
Apr-27-23 04:30PM	Cellectis to Report First Quarter 2023 Financial Results on May 4, 2023 (GlobeNewswire)
Apr-24-23 04:30PM	Cellectis Implements CLLS52 for the First Time in the Clinic with Sanofis Alemtuzumab (GlobeNewswire)
Apr-17-23 02:00AM	Cellectis Presents Preclinical Data on TALEN®-edited MUC1 CAR T-cells to Enhance Efficacy in Targeting Triple Negative Breast Cancer at the American Association for Cancer Research (AACR) Annual Meeting (GlobeNewswire)
Apr-12-23 04:30PM	Monthly information on share capital and company voting rights (GlobeNewswire)
Apr-11-23 04:30PM	Cellectis Announces Dosing of the First Patient in Europe with its In-house Manufactured Product Candidate UCART22 (GlobeNewswire)
Apr-04-23 04:30PM	Cellectis enters into warrant agreement with the European Investment Bank related to credit facility agreement and announces the drawdown of the first tranche of 20 million (GlobeNewswire)

Cellectis SA operates as a clinical stage biotechnological company, which engages in gene-editing platform to develop cell and gene therapies. The company was founded by David J. Sourdive and Andre Choulika on February 20, 1999 and is headquartered in Paris, France.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

CLLS

Cellectis ADR

Upgrade your FINVIZ experience